2 results
Approved WMOCompleted
Primary objective: To determine if apixaban is noninferior to warfarin (INR target range 2.0-3.0) in the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism, in subjects with AF and at lease one additional risk factor for…
Approved WMOCompleted
To investigate if determining dry-weight with the assistance of bioelectrical impedance analysis compared to the current practice will result in a better blood pressure control.